Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12725
Title: A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults.
Authors: Gattas, David J;Rajbhandari, Dorrilyn;Bradford, Celia;Buhr, Heidi;Lo, Serigne;Bellomo, Rinaldo
Affiliation: 1Intensive Care Service, Royal Prince Alfred Hospital, Camperdown, NSW, Australia. 2Critical Care & Trauma Division, George Institute for Global Health, Sydney, NSW, Australia. 3Intensive Care Department, Royal North Shore Hospital, St Leonards, NSW, Australia. 4Australian and New Zealand Intensive Care Research Centre, Melbourne, VIC, Australia. 5Intensive Care Department, Austin Hospital, Melbourne, VIC, Australia.
Issue Date: 6-Apr-2015
Citation: Critical Care Medicine; 43(8): 1622-9
Abstract: To determine whether regional anticoagulation of continuous renal replacement therapy circuits using citrate and calcium prolongs circuit life and/or affects circulating cytokine levels compared with regional anticoagulation using heparin and protamine.Multicenter, parallel group randomized controlled trial.Seven ICUs in Australia and New Zealand.Critically ill adults requiring continuous renal replacement therapy.Patients were randomized to receive one of two methods of regional circuit anticoagulation: citrate and calcium or heparin and protamine.The primary outcome was functional circuit life measured in hours, assessed using repeated events survival analysis. In addition, we measured changes in interleukin-6, interleukin-8, and interleukin-10 blood levels. We randomized 212 subjects who were treated with 857 continuous renal replacement therapy circuits (median 2 circuits per patient [interquartile range, 1-6], 390 in citrate group vs 467 in heparin group). The groups were well matched for baseline characteristics. Patients receiving regional continuous renal replacement therapy anticoagulation with heparin and protamine were more likely to experience circuit clotting than those receiving citrate and calcium (hazard ratio, 2.03 [1.36-3.03]; p < 0.0005; 857 circuits). The median lifespan of the first study circuit in each patient was 39.2 hours (95% CI, 32.1-48.0 hr) in the citrate and calcium group versus 22.8 hours (95% CI, 13.3-34.0 hr) in the heparin and protamine group (log rank p = 0.0037, 204 circuits). Circuit anticoagulation with citrate and calcium had similar effects on cytokine levels compared with heparin and protamine anticoagulation. There were more adverse events in the group assigned to heparin and protamine anticoagulation (11 vs 2; p = 0.011).Regional citrate and calcium anticoagulation prolongs continuous renal replacement therapy circuit life compared with regional heparin and protamine anticoagulation, does not affect cytokine levels, and is associated with fewer adverse events.
Internal ID Number: 25853591
URI: http://ahro.austin.org.au/austinjspui/handle/1/12725
DOI: 10.1097/CCM.0000000000001004
URL: http://www.ncbi.nlm.nih.gov/pubmed/25853591
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.